Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
The AI response makes multiple formulation/composition generalizations about nebivolol tablets (excipients, fillers, binders, disintegrants, lubricants, film coating, colorants, salt forms, and release characteristics) but the provided BYSTOLIC label excerpts do not support these claims. The only label-supported parts concern the indication (hypertension), dosing ranges, contraindications, certain warnings, and that BYSTOLIC tablets contain nebivolol hydrochloride equivalents (2.5/5/10/20 mg) and storage conditions.
Category Scores
Accurate Statements
The exact composition of a specific nebivolol product can be found in the package insert or patient leaflet.
Not supported or contradicted by the provided BYSTOLIC label excerpts (no label excerpt provided about where to find composition/ingredients).
Different nebivolol products can have different strengths measured in mg per tablet.
Supported only in the sense that BYSTOLIC is available in tablets containing nebivolol hydrochloride equivalent to 2.5, 5, 10, and 20 mg of nebivolol (Label 16).
Unsupported Statements
Nebivolol products commonly contain the active ingredient nebivolol, often as nebivolol hydrochloride in tablets.
The provided label excerpt specifies BYSTOLIC contains nebivolol hydrochloride equivalent (Label 16) but does not support broad statements about other nebivolol products or how they are commonly formulated.
Nebivolol tablet formulations typically include non-medicinal ingredients (excipients) to help the tablet dissolve, disintegrate, and stay stable.
No excipient/composition details are provided in the supplied BYSTOLIC label excerpts.
Nebivolol tablets may include fillers or diluents (e.g., lactose-based materials).
No excipient list or lactose/diluents information is included in the provided label excerpts.
Nebivolol tablets may include binders to help the tablet hold together.
No binder information is included in the provided label excerpts.
Nebivolol tablets may include disintegrants to help the tablet break apart.
No disintegrant information is included in the provided label excerpts.
Nebivolol tablets may include lubricants to help manufacturing flow.
No lubricant information is included in the provided label excerpts.
Nebivolol tablets may include film-coating materials.
No coating information is included in the provided label excerpts.
Nebivolol tablets may include colorants in some products.
No colorant information is included in the provided label excerpts.
Different nebivolol products can have different salt forms (e.g., nebivolol hydrochloride).
The provided label only supports that BYSTOLIC uses nebivolol hydrochloride equivalent; it does not support claims about other salt forms across products.
Different nebivolol products can have different release characteristics (immediate versus extended release, if applicable).
No release/ER/IR formulation information is included in the provided BYSTOLIC label excerpts.
Different nebivolol products can have different excipients and tablet coating.
No excipient/coating differences across products are described in the provided label excerpts.
Formulation differences in nebivolol products can matter for allergies and dietary restrictions (for example, lactose-containing excipients).
No allergy/dietary restriction or lactose-excipient information is included in the provided label excerpts.
Formulation differences in nebivolol products can affect how the tablet looks or breaks apart.
No label support is provided for any specific relationship between excipients/coatings and appearance/break-apart behavior.
Different product versions of nebivolol can have formulation differences, including excipients and manufacturing details.
The provided label excerpts do not include general statements about formulation/manufacturing differences between product versions beyond the strengths and tablet availability.
Contradictions
Important Omissions
The AI did not provide any label-supported contraindications, key warnings/precautions, or dosing specifics for BYSTOLIC beyond general composition statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are mainly about general formulation/composition possibilities and do not directly claim specific patient risks or dosing errors. However, absence of label support reduces reliability of any excipient-related statements (e.g., lactose) for allergy/dietary considerations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple formulation/composition and product-comparison claims are not supported by the provided BYSTOLIC label excerpts.
Suggested Improvement
Limit claims to what the provided label excerpts support (e.g., BYSTOLIC indication for hypertension, dosing ranges including starting dose/titration, contraindications list, and that BYSTOLIC tablets contain nebivolol hydrochloride equivalents of 2.5/5/10/20 mg and storage conditions). Omit or qualify excipient/salt/release-characteristic statements unless the corresponding FDA label composition/release information is provided.